Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Neuro-Oncology
Published in: Journal of Neuro-Oncology 2/2014

01-04-2014 | Clinical Study

Expression and localization of serine protease Htra1 in neuroblastoma: correlation with cellular differentiation grade

Authors: Velia D’Angelo, Giulia Pecoraro, Paolo Indolfi, Adriana Iannotta, Vittoria Donofrio, Maria Elena Errico, Cristiana Indolfi, Maria Ramaglia, Angela Lombardi, Martina Di Martino, Vincenzo Gigantino, Alfonso Baldi, Michele Caraglia, Antonio De Luca, Fiorina Casale

Published in: Journal of Neuro-Oncology | Issue 2/2014

Login to get access

Abstract

Neuroblastoma (NB) is a paediatric tumor that arises from neural crest and shows heterogeneous clinical and biological features. The serine-protease high temperature requirement A1 (HtrA1) has a pivotal role in both cell proliferation and differentiation. Here we report the expression and localization of HtrA1 in NB tumor samples to assess HtrA1 role as a possible new biomarker of cellular differentiation in NB patients. HtrA1 protein expression by Western Blot assay was performed in 60 tissue samples of 50 children with NB and 10 children with ganglioneuroblastoma (GNB). HtrA1 was expressed in 56/60 (93.3 %) samples with different expression levels: low levels in 36/56 samples (64.3 %) and high levels in 20/56 (35.7 %). Higher levels were found in 1, 2 and 4s stages (80 %), whereas 3 and 4 stages (20 %) showed a low expression, with a statistically significant difference (p = 0.003). Among not amplified N-MYC group, 28 (60 %) had low/absent expression of HtrA1: seven with recurrent disease and negative outcome and 21 in continuous complete remission (CCR), whereas all samples with high expression of HtrA1 (17/44) were in CCR (p = 0.03). The immunohistochemical analysis showed localization of HtrA1 in differentiated areas higher than in undifferentiated areas where the protein was absent. Moreover, HtrA1 was highly expressed in all GNB samples. In conclusion, the over-expression of HtrA1 is correlated to cellular differentiation grade and stage of NB at diagnosis. Moreover, HtrA1 could represent a new marker of undifferentiation and biological aggressiveness of NB.
Literature
1.
Heck JE, Ritz B, Hung RJ, Hashibe M, Boffetta P (2009) The epidemiology of neuroblastoma: a review paediatric. Perinat Epidemiol 23:125–143CrossRef
2.
Ries L, Eisner M, Kosary C, Hankey B, Miller B, Clegg L (2005) SEER cancer statistics review, 1975–2002. National Cancer Institute, Bethesda
3.
Spix C, Pastore G, Sankila R, Stiller CA, Steliarova-Foucher E (2006) Neuroblastoma incidence and survival in European children (1978–1997): report from the Automated Childhood Cancer Information System project. Eur J Cancer 42:2081–2091PubMedCrossRef
4.
Gurney JG, Ross JA, Wall DA, Bleyer WA, Severson RK, Robison LL (1997) Infant cancer in the U.S.: histology-specific incidence and trends, 1973 to 1992. J Pediatr Hematol Oncol 19:428–432PubMedCrossRef
5.
Gray H, Standring S, Ellis H, Berkovitz BKB (2005) Gray’s anatomy: the anatomical basis of clinical practice, 39th edn. Elsevier Churchill Livingstone, Edinburgh
6.
Shimada H, Ambros IM, Dehner LP, Hata J, Joshi VV, Roald B, Stram DO, Gerbing RB, Lukens JN, Matthay KK, Castleberry RP (1999) The international neuroblastoma pathology classification (the Shimada system). Cancer 86:364–372PubMedCrossRef
7.
Clausen T, Southan C, Ehrmann M (2002) The HtrA family of proteases: implications for protein composition and cell fate. Mol Cell 10:443–445PubMedCrossRef
8.
Zumbrunn J, Trueb B (1997) Localization of the gene for a serine protease with IGF binding domain (PRSS11) to human chromosome10q25.3-q26.2. Genomics 45:461–462PubMedCrossRef
9.
Hu SI, Carozza M, Klein M, Nantermet P, Luk D, Crowl RM (1998) Human HtrA, an evolutionarily conserved serine protease identified as a differentially expressed gene product in osteoarthritic cartilage. J Biol Chem 273:34406–34412PubMedCrossRef
10.
Gray CW, Ward RV, Karran E, Turconi S, Rowles A, Viglienghi D, Southan C, Barton A, Fantom KG, West A, Savopoulos J, Hassan NJ, Clinkenbeard H, Hanning C, Amegadzie B, Davis JB, Dingwall C, Livi GP, Creasy CL (2000) Characterization of human HtrA2, a novel serine protease involved in the mammalian cellular stress response. Eur J Biochem 267:5699–5710PubMedCrossRef
11.
Nie GY, Hampton A, Li Y, Findlay JK, Salamonsen LA (2003) Identification and cloning of two isoforms of human high-temperature requirement factor A3 (HtrA3), characterisation of its genomic structure and comparison of its tissue distribution with HtrA1 and HtrA2. Biochem J 37:39–48CrossRef
12.
Oka C, Tsujimoto R, Kajikawa M, Koshiba-Takeuchi K, Ina J, Yano M, Tsuchiya A, Ueta Y, Soma A, Kanda H, Matsumoto M, Kawaichi M (2004) HtrA1 serine protease inhibits signaling mediated by Tgf-β family proteins. Development 131:1041–1053PubMedCrossRef
13.
Shridhar V, Sen A, Chien J, Staub J, Avula R, Kovats S, Lee J, Lillie J, Smith DI (2002) Identification of underexpressed genes in early- and late-stage primary ovarian tumors by suppression subtraction hybridization. Cancer Res 62:262–270PubMed
14.
Baldi A, De Luca A, Morini M, Battista T, Felsani A, Baldi F, Catricala C, Amantea A, Noonan DM, Albini A, Natali PG, Lombardi D, Paggi MG (2002) The HtrAl serine protease is down-regulated during human melanoma progression and repress growth of metastatic melanoma cells. Oncogene 21:6684–6688PubMedCrossRef
15.
Chien J, Staub J, Hu SI, Erickson-Johnson MR, Couch FJ, Smith DI, Crowl RM, Kaufmann SH, Shridhar V (2004) A candidate tumor suppressor HtrA1 is down-regulated in ovarian cancer. Oncogene 23:1636–1644PubMedCrossRef
16.
De Luca A, De Falco M, Severino A, Campioni M, Santini D, Baldi F, Paggi MG, Baldi A (2003) Distribution of the serine protease HtrA1 in normal human tissues. J Histochem Cytochem 51:1279–1284PubMedCrossRef
17.
Zumbrunn J, Trueb B (1996) Primary structure of a putative serine protease specific for IGF-binding proteins. FEBS Lett 398:187–192PubMedCrossRef
18.
De Luca A, De Falco M, Fedele V, Cobellis L, Mastrogiacomo A, Laforgia V, Tuduce IL, Campioni M, Giraldi D, Paggi MG, Baldi A (2004) The serine protease HtrA1 is upregulated in the human placenta during pregnancy. J Histochem Cytochem 52:885–892PubMedCrossRef
19.
Campioni M, Severino A, Manente L, Tuduce IL, Toldo S, Caraglia M, Crispi S, Ehrmann M, He X, Maguire J, De Falco M, De Luca A, Shridhar V, Baldi A (2010) The serine protease HtrA1 specifically interacts and degrades the tuberous sclerosis complex 2 protein. Mol Cancer Res 8:1248–1260PubMedCrossRef
20.
De Luca A, De Falco M, De Luca L, Penta R, Shridhar V, Baldi F, Campioni M, Paggi MG, Baldi A (2004) Pattern of expression of HtrA1during mouse development. J Histochem Cytochem 52:1609–1617PubMedCrossRef
21.
Pizzo PA, Poplack DG (eds) (2006) Principles and pratice of pediatric oncology, 5th edn. Lippincott Williams & Wilkins, Philadelphia
22.
Seelam B, Kayisli UA, Mulayim N, Arici A (2001) Regulation of Fas ligand expression by estradiol and progesterone in human endometrium. Biol Reprod 65:979–985CrossRef
23.
Bowden MA, Di Nezza-Cossens LA, Jobling T, Salamonsen LA, Nie G (2006) Serine proteases HtrA1 and HtrA3 are down-regulated with increasing grades of human endometrial cancer. Gynecol Oncol 103:253–260PubMedCrossRef
24.
Suzuki Y, Takahashi-Niki K, Akagi T, Hashikawa T, Takahashi R (2004) Mitochondrial protease Omi/HtrA2 enhances caspase activation through multiple pathways. Cell Death Differ 11:208–216PubMedCrossRef
25.
Spugnini EP, Cardillo I, Verdina A, Crispi S, Saviozzi S, Calogero R, Nebbioso A, Altucci L, Cortese G, Galati R, Chien J, Shridhar V, Vincenzi B, Citro G, Cognetti F, Sacchi A, Baldi A (2006) Piroxicam and cisplatin in a mouse model of peritoneal mesothelioma. Clin Cancer Res 12(20):6133–6143PubMedCrossRef
26.
Esposito V, Campioni M, De Luca A, Spugnini EP, Baldi F, Cassandro R, Mancini A, Vincenzi B, Groeger A, Caputi M, Baldi A (2006) Analysis of HtrA1 serine protease expression in human lung cancer. Anticancer Res 26:3455–3460PubMed
27.
Narkiewicz J, Klasa-Mazurkiewicz D, Zurawa-Janicka D, Skorko-Glonek J, Emerich J, Lipinska B (2008) Changes in mRNA and protein levels of human HtrA1, HtrA2 and HtrA3 in ovarian cancer. Clin Biochem 41:561–569PubMedCrossRef
28.
Drubin DA, Clawson GA (2004) Spontaneous transformation of an immortalized hepatocyte cell line: potential role of a nuclear protease. Cancer Lett 15:39–48CrossRef
29.
Lázcoz P, Muñoz J, Nistal M, Pestaña A, Encío IJ, Castresana JS (2007) Loss of heterozygosity and microsatellite instability on chromosome arm 10q in neuroblastoma. Cancer Genet Cytogenet 1:1–8CrossRef
30.
Chien J, Aletti G, Baldi A, Catalano V, Muretto P, Keeney GL, Kalli KR, Staub J, Ehrmann M, Cliby WA, Lee YK, Bible KC, Hartmann LC, Kaufmann SH, Shridhar V (2006) Serine protease HtrA1modulates chemotherapy-induced cytotoxicity. J Clin Invest 116:1994–2004PubMedCentralPubMedCrossRef
Metadata
Title
Expression and localization of serine protease Htra1 in neuroblastoma: correlation with cellular differentiation grade
Authors
Velia D’Angelo
Giulia Pecoraro
Paolo Indolfi
Adriana Iannotta
Vittoria Donofrio
Maria Elena Errico
Cristiana Indolfi
Maria Ramaglia
Angela Lombardi
Martina Di Martino
Vincenzo Gigantino
Alfonso Baldi
Michele Caraglia
Antonio De Luca
Fiorina Casale
Publication date
01-04-2014
Publisher
Springer US
Published in
Journal of Neuro-Oncology / Issue 2/2014
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-014-1387-4

Other articles of this Issue 2/2014

Journal of Neuro-Oncology 2/2014 Go to the issue

Clinical Study

Re-irradiation and bevacizumab in recurrent high-grade glioma: an effective treatment option

Clinical Study

Fractionated stereotactic radiosurgery for patients with brain metastases

Topic Review

End-of-life symptoms and care in patients with primary malignant brain tumors: a systematic literature review

Laboratory Investigation

Characterization of fenofibrate-mediated anti-proliferative pro-apoptotic effects on high-grade gliomas and anti-invasive effects on glioma stem cells

Letter to the Editor

Upfront chemotherapy with CCNU alone for adults’ low-grade gliomas: a clinical analysis

Clinical Study

Benefit of tumor resection for recurrent glioblastoma